Interferon‐α‐2b Aerosol Inhalation is Associated with Improved Clinical Outcomes in Patients with Coronavirus Disease‐2019

Retrospective study (n=1401 in China of which 852 on IFN‐α‐2b) suggests use of 5,000,000 U of IFN‐α‐2b via aerosol inhalation twice daily may be linked to improved clinical outcomes in patients with COVID‐19 (composite endpoints in 3.8% vs 9.3% non‐IFN‐α‐2b group; p < 0.001).

SPS commentary:

The primary outcome of study was a composite measure consisting of mechanical ventilation, intensive care unit admission, and death.

British Journal of Clinical Pharmacology